NIPH Clinical Trials Search

Basic Information

Recruitment status
Health condition(s) or Problem(s) studied	Pancreatic cancer
Date of first enrollment	14/12/2006
Target sample size
Countries of recruitment
Study type	Interventional
Intervention(s)	investigational material(s) Generic name etc : erlotinibhydrochloride INN of investigational material : Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : 100mg

Outcome(s)

Primary Outcome	Safety (feasibility), efficacy
Secondary Outcome

Key inclusion & exclusion criteria

Age minimum	Not applicable
Age maximum	Not applicable
Gender	Both
Include criteria	Inclusion criteria - Histologically or cytologically confirmed diagnosis of adenocarcinoma or adenosquamous of the pancreas cancer which is unresectable (locally advanced or metastatic). - ECOG performance status (PS) of 0, 1 or 2. - Adequate organ functions Exclusion criteria - The patient is currently suffering from such pulmonary disorders as sudden pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, active radioactive pneumonia, or drug-related pneumonia, or he/she has a history of such disease. - Patients have thoracic radiotherapy. - Prior treatment with Gemcitabine - Patients who have had treatment with any investigational drug within 4 weeks prior to entry. - Patients who have history of serious hypersensitivity reactions with any medicine.
Exclude criteria